Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma, sold RPRX on Jun 23, 2026
Data as of Oct 16
▼ SELL$1.8M32,408 shares at $54.11Christopher Hite EVP & Chairman, PartneringRPRX Royalty Pharma plc
- Traded
- Jun 23, 2026
- Disclosed
- Jun 25, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
RPRX since disclosure
+11.5%
after the sale
Similar stocks (XLV) since disclosure
+13.5%
XLV — its sector index fund
Change in closing price from Jun 25, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLChristopher Hite EVP & Chairman, PartneringRPRX Royalty Pharma plc$6.4Mdisclosed Jun 25 · filed 2 days after the trade